Sagimet Biosciences (SGMT) stock

Developing medicines , market cap $647M

Developing medicines

Worth $647M

$10.89

+0.55%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Average

In its industry

#65of 281

Biotech

Checks firing

8of 14

Trending up

From 52-week high

-4.9%

under its best in a year

SGMT's Quality Score rose 2 points on Tue, Nov 10, to 7. Its price got close to its high of the past year (2 chart checks started).

Follow SGMT's trial news. Pro members can get an alert when Sagimet Biosciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when SGMT files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“Phase 1 clinical trial results anticipated in 2026, Phase 2 proof of concept clinical trial anticipated to”Trial data · SEC filing · Sep 30

Why is SGMT up?

Up 19% from Nov 5 to Nov 10.

Sagimet Biosciences rose 19% from Nov 5 to Nov 10. 11 points of it came on Nov 9.

Sources: Price history, Nov 10, 2026

1 more reason, free with an account →The timeline and its peers, for Pro members.

Key facts on SGMT

Key facts on SGMT
The chart	Stronger than 93% of stocks above every average
Latest filing	8-K, Oct 1 Signed a material agreement

1 more reason behind SGMT's 7, free with an account →4 more reasons behind SGMT's 7, for Pro members.

SGMT in the news

ReportExpected to report Thursday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It fell after 3 of its last 4 reports, -2.4% on average. Past reports ›

SGMT catalysts

Coming up

After its last 4 reports it closed -2.4% on average, higher 1 of 4 times.

3 more coming up, with sizes and sources, for Pro members.

What's next for SGMT, and how long its cash lasts

Next step the company has named

2026“Phase 1 clinical trial results anticipated in 2026, Phase 2 proof of concept clinical trial anticipated to”Trial data · SEC filing · Sep 30

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: Denifanstat in Participants With Moderate to Severe AcnePhase 3 · Recruiting · 800 people · main data estimated Aug 2027 · NCT07863193

1 more trial, 3 more milestones and 48 filings, for Pro members.

Cash runway

The company says its cash lasts through 2028 (8-K, Sep 30).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Aug 15, 2024)
At-the-market share sales program (424B5, filed Aug 14, 2025)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

Director George Kemble sold 350,987 shares on Aug 14, under a planned sale. 8 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when David Happel buys or sells

For Pro members: every trade, and David Happel’s 14 filings and quotes.

Get an alert when SGMT files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why SGMT scores 7

Averagefor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. SGMT scores 7 today, against a median of 2 over its last 20 recorded sessions.

+8Chart checks 8 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on SGMT and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when SGMT's Quality Score turns up

A free account. No card.

How SGMT ranks in Biotech

SGMT is #65 of 281 by Quality Score.

How SGMT ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	SCTXScribe Therapeutics		Open for its score
	SEPNSepterna		Open for its score
	SIONSionna Therapeutics		Open for its score
	SLDBSolid Biosciences		Open for its score
65	SGMTSagimet Biosciences	8/14	7

When does SGMT report earnings, and what happens after?

Expected to report Thu Nov 12, before the open (in 2 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+3.8%-0.5%-0.5%

Mar 11May 12Aug 11

Reported	When	Gap	Reaction	5 days
Aug 11, 2026Before open	Before open	0.0%	-0.5%	+9.0%
May 12, 2026Before open	Before open	-1.3%	-0.5%	-13.4%
Mar 11, 2026Before open	Before open	+4.3%	+3.8%	-6.2%

SGMT closed higher after 1 of its last 4 reports.

All 4 reports, and SGMT's Quality Score going into each

Everyone reporting earnings this week

SGMT has 8 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on SGMT, and all 14 on every stock.Get in free →

SGMT RSI today: 60.0, above its 50-day and 200-day averages

Not scored

RSI 60.0, MACD above signal, above both averages. Not scored.13 readings

The deep dive on SGMT

What it does and how it makes money5 findings"We are also eligible to receive from Ascletis tiered royalty payments ranging from high single digit to mid-teen percentages on annual net sales of denifanstat and other products containing licensed compounds in the Territory, subject to customary reductions." (10-K for fiscal 2023)SEC filing · Mar 25, 2024"In addition, we own and/or have control of patents that have been granted in various jurisdictions including Australia, Argentina, Brazil, countries across Europe, Japan, China, South Korea, India, Israel, Macau, Mexico, New Zealand, Taiwan, and South Africa, which are expected to expire in 2032 …" (10-K for fiscal 2023)SEC filing · Mar 25, 2024
Where it stands1 findingFor Pro members1 finding on where SGMT stands: its cash, debt, and share count, for Pro members
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades SGMT, for Pro members

6 more findings on SGMT, each with its source, for Pro members.

SGMT share count over time

65% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of SGMT outstanding, as filed
Shares outstanding	As of
30.7M	Nov 8, 2024
30.7M	Aug 9, 2024
30.4M	May 10, 2024
21.4M	Nov 9, 2023

Offerings, shelves, and splits of SGMT, from its filings
From its filings	Filed
Priced a sale of shares	Oct 1, 2026
Priced a sale of shares	Apr 28, 2026
Set up an at-the-market program for up to $75M of shares, about 12% of its market value	Aug 14, 2025
Registered shares for a later sale (S-3)	Aug 15, 2024

SGMT insider trades

2 insiders sold $579K across 2 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellDavid Happel$497KPresident & CEOat $7.76 on Jul 20, filed Jul 22

SellDavid HappelPresident & CEO$497Kat $7.76 on Jul 20, filed Jul 22

SGMT's officers and directors

Officers and directors with a Form 4 in the last 12 months.

David HappelPresident & CEO · 2 trades
Thierry ChaucheChief Financial Officer · 1 trade
Elizabeth RozekChief Legal & Admin. Officer · 2 trades
Eduardo Bruno MartinsChief Medical Officer · 1 trade
George KembleDirector · 4 trades

See insider trades by person

Which ETFs hold SGMT?

In ETFs: SGMT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Sagimet Biosciences

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

16 employeesFoster City, CAsagimet.com

What Sagimet Biosciences says it competes with

“The biopharmaceutical industry is characterized by intense competition and rapid innovation.”

From its annual report, SEC filing · Mar 25, 2024

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on SGMT and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move SGMT's score: 8 things
10 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJul 22David Happel sold SGMT$497K at $7.76, filed Jul 22

Alerts are optional.

See SGMT's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: SGMT's Quality Score is 7 (Average), #65 of 281 in Biotech. Insiders sold $579K in the last 6 months (Form 4).

What does SGMT's Quality Score say?

SGMT scores 7 today, which Breakaway calls Average. It is #65 of 281 in Biotech by Quality Score, with 8 of 14 chart checks firing. Up 19% from Nov 5 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is SGMT's Quality Score?

SGMT scores 7 today, which Breakaway calls Average (6 to 10). That is #65 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SGMT's 7.

Are insiders buying SGMT?

2 insiders sold $579K across 2 filings in the last 6 months. No open-⁠market buys on record. The newest is David Happel, President & CEO, who sold $497K on Jul 20. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.